COST-EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS FOLFIRI VERSUS FOLFIRI IN PATIENTS WITH METASTATIC COLORECTAL CANCER: A UK PERSPECTIVE

被引：0
|
作者：
Gyldmark, M. [1 ]
Aultman, R. [1 ]
Siebert, U. [2 ]
Sabate, E. [3 ]
机构：
[1] F Hoffmann La Roche Ltd, Basel, Switzerland
[2] UMIT Univ Hlth Sci Med Informat & Technol, Hall In Tirol, Austria
[3] F Hoffmann La Roche Pharmaceut AG, Basel, Switzerland
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)73306-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A49 / A49
页数：1
相关论文
共 50 条
  • [41] Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
    Vera Gorbunova
    J. Thaddeus Beck
    Ralf-Dieter Hofheinz
    Pilar Garcia-Alfonso
    Marina Nechaeva
    Antonio Cubillo Gracian
    Laszlo Mangel
    Elena Elez Fernandez
    Dustin A. Deming
    Ramesh K. Ramanathan
    Alison H. Torres
    Danielle Sullivan
    Yan Luo
    Jordan D. Berlin
    British Journal of Cancer, 2019, 121 : 429 - 430
  • [42] Cost-effectiveness analysis of FOLFOXIRI/FOLFOXIRI and mFOLFOX6/FOLFIRI treatment in first-line and second-line chemotherapy for metastatic colorectal cancer
    Li, Xianglian
    Bao, Jianan
    Ma, Jingjing
    BMJ OPEN, 2025, 15 (03):
  • [43] Cetuximab A Guide to Its Use in Combination with FOLFIRI in the First-Line Treatment of Metastatic Colorectal Cancer in the USA
    Lyseng-Williamson, Katherine A.
    MOLECULAR DIAGNOSIS & THERAPY, 2012, 16 (05) : 317 - 322
  • [44] SAFETY AND EFFICACY OF BEVACIZUMAB WITH FIRST-LINE FOLFIRI FOR METASTATIC COLORECTAL CANCER: SINGLE CENTER EXPERIENCE
    De Sanctis, R.
    Longo, F.
    Gori, B.
    Zivi, A.
    Del Signore, E.
    Proietti, E.
    De Filippis, L.
    Stumbo, L.
    Quadrini, S.
    Di Seri, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 145 - 145
  • [45] A comparison of efficacy of first-line chemotherapy regimens for metastatic colorectal cancer (mCRC): FOLFIRI plus bevacizumab vs. XELIRI plus bevacizumab
    Ocvirk, J.
    Rebersek, M.
    Boc, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 336 - 336
  • [46] Safety and efficacy of bevacizumab with first-line FOLFIRI for metastatic colorectal cancer: Single center experience
    Longo, F.
    De Sanctis, R.
    Quadrini, S.
    Stumbo, L.
    Del Signore, E.
    Gori, B.
    De Filippis, L.
    Di Seri, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 91 - 92
  • [47] CetuximabA Guide to Its Use in Combination with FOLFIRI in the First-Line Treatment of Metastatic Colorectal Cancer in the USA
    Katherine A. Lyseng-Williamson
    Molecular Diagnosis & Therapy, 2012, 16 : 317 - 322
  • [48] A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer
    R López
    M Salgado
    M Reboredo
    C Grande
    J C Méndez
    M Jorge
    C Romero
    G Quintero
    J de la Cámara
    S Candamio
    British Journal of Cancer, 2010, 103 : 1536 - 1541
  • [49] A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer
    Lopez, R.
    Salgado, M.
    Reboredo, M.
    Grande, C.
    Mendez, J. C.
    Jorge, M.
    Romero, C.
    Quintero, G.
    de la Camara, J.
    Candamio, S.
    BRITISH JOURNAL OF CANCER, 2010, 103 (10) : 1536 - 1541
  • [50] ESTIMATION OF COSTS OF FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) WITH FOLFIRI, FOLFOX OR XELOX PLUS BEVACIZUMAB, IN FIVE MEXICAN INSTITUTIONS
    Calderillo, Ruiz G.
    VALUE IN HEALTH, 2011, 14 (07) : A539 - A539
12345